Showing: 1 - 8 of 8 RESULTS

Summit, Colorado Center for Personalized Medicine to Develop Saliva Tests for COVID, Head & Neck Cancer

AURORA, Colo., Oct. 14, 2020 /PRNewswire/ — Summit Biolabs, Inc., an early-stage molecular diagnostics company specializing in saliva-based testing for COVID-19 and head & neck cancer, and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus announced today a broad strategic collaboration involving research, development and commercialization of saliva liquid-biopsy tests for early cancer detection and diagnosis of COVID-19 and other viral contagions.

The CCPM holds one of the largest research biobanks in the United States with clinical data from more than 8.7 million de-identified patient records and plans to integrate the data with personalized genomic information.

“This partnership brings two innovative programs together to optimize COVID testing at a time when it’s desperately needed,” says Kathleen Barnes, Ph.D., Professor and Director of CCPM at the University of Colorado Anschutz Medical Campus. “Collaborations like this are crucial in moving research forward and advancing and expanding clinical testing to as many members of our community as possible. Working with Summit Biolabs, and leveraging technology developed by our colleagues here at the Anschutz Medical Campus, will help us achieve these goals and establish a non-invasive testing process that will benefit patients in Colorado and beyond.”

Summit Biolabs is developing breakthrough tests to improve the detection of COVID-19 and to advance the early detection of human cancers, including head & neck cancer, using simple, non-invasive saliva liquid-biopsy technology developed by Dr. Shi-Long Lu and colleagues at the University of Colorado Anschutz Medical Campus. Head & neck cancer has been scientifically overlooked, yet is medically important. Summit Biolabs’ research foundation and competency in head & neck cancer diagnosis enabled the company’s pivot to saliva-based testing for coronavirus, COVID-19.

“We are excited to collaborate with CCPM to develop and commercialize Summit Biolabs’ portfolio of developmental saliva or non-blood liquid-biopsy tests.” said Bob Blomquist, Chief Executive Officer at Summit Biolabs. “This collaboration broadens and strengthens Summit Biolabs’ ability to bring to market life-changing saliva liquid-biopsy tests that ultimately enable better treatment and improved outcomes for patients.”

About Summit Biolabs

Summit Biolabs is harnessing the power of saliva-based diagnostics to address critical challenges in COVID-19 and head & neck cancer testing. Founded on the discoveries of Dr. Shi-Long Lu, Associate Professor of Otolaryngology, Summit Biolabs is being spun out from the University of Colorado Anschutz Medical Campus.

Summit Biolabs is pioneering early detection of head & neck cancer recurrence using a first of its kind saliva liquid-biopsy test, HNKlear. HNKlear is a proprietary, non-invasive saliva test that provides more effective, more accurate, and earlier detection of head and neck cancer recurrence than traditional diagnostic methods. Summit Biolabs is leveraging its core competencies in saliva-based molecular diagnostics and viral nucleic acid testing (i.e., oral oncogenic human papillomavirus detection) to diagnose COVID-19. Along with our clinical and laboratory partners, Summit Biolabs is developing the first comprehensive panel of highly-accurate saliva-based tests for COVID-19 infection, quantitation, and immune response. Summit Biolabs is headquartered in Aurora, Colorado.

About

Scientists develop new precision medicine approach for pancreatic cancer

Scientists from the University of Glasgow are developing new ways to predict who will respond to drugs targeting damaged DNA in pancreatic cancer. 

Publishing their findings in Gastroenterology, the team used cells grown in the lab (cell lines) and mini replicas of patients’ tumours (organoids) to identify molecular markers that can predict which tumours will respond to a number of drugs that target damaged DNA.  

Dr David Chang, from the University of Glasgow’s Institute of Cancer Sciences, called the results “a huge breakthrough in terms of what might be possible for future treatments.”

The team are now taking their strategy forward into a clinical trial to help doctors work out who might respond to the drugs, either alone or in combination. The trial – PRIMUS-004 – is part of our Precision Panc platform for pancreatic cancer, which aims to increase opportunities for people with pancreatic cancer to join clinical trials and to develop new treatment strategies. 

“The strategy we’ve developed is extremely promising, and we’re very pleased and proud to see it now be taken into clinical trial.” – Dr David Chang

Precision Panc

In 2017, we invested £10 million in Precision Panc to speed up our understanding of pancreatic and work towards more tailored treatment for the disease. It’s our biggest standalone in pancreatic cancer research to date, with the aim of driving progress for pancreatic cancer, where survival has remained stubbornly low.

A major barrier to treating pancreatic effectively is that there are very few treatment options. But there are some pancreatic cancers that cannot repair damaged DNA, which make them vulnerable to some new treatments. This is what researchers are aiming to target.

“We urgently need new ways to treatment pancreatic cancer,” says Michelle Mitchell, Cancer Research UK’s chief executive. “The Precision Panc study offers a dynamic way to explore new tailored treatments, and it’s fantastic that we know have new drug candidates to add to the PRIMUS-004 trials.”

A menu of trials

PRIMUS-004 is a mid-stage (phase 2) clinical trial testing the new approach to help match people with pancreatic that’s spread to new targeted treatments.

The trial is due to open this month and will be an option for people who’ve already had platinum chemotherapy and whose cancer has a fault that means it cannot repair damaged DNA. Funded by AstraZeneca and endorsed by Cancer Research UK, it’s the first trial in the UK that will test this precision medicine approach in pancreatic cancer. 

PRIMUS-004 is the fourth trial that Precision Panc will feed into, with 3 studies already linked to the platform – PRIMUS-001 for people with pancreatic cancer that’s spread and PRIMUS-002, which is testing the benefits of 2 different chemotherapy combos before surgery. 

Another trial – PRIMUS-005, involving patients with locally advanced cancer – is also due to open this month. 

As well as helping to give people with pancreatic cancer better trial options, the Precision Panc study is also collecting and analysing tumour samples and looking for new biomarkers to

Scientists develop new ‘precision medicine’ approach to treating damaged DNA in pancreatic cancer

dna
Credit: CC0 Public Domain

Scientists have developed a new “precision medicine” approach to treating the damaged DNA in the cancer cells of Pancreatic Cancer patients.

The findings mark an important step forward for potential treatment options for pancreatic cancer, improving the options and outcomes for a disease where survival rates have remained stubbornly low.

The study detailing the approach—led by the University of Glasgow and published in Gastroenterology—used cell lines and organoids that were generated from patients with pancreatic cancer to develop new molecular markers that can predict who will respond to drugs targeting DNA damage.

The researchers tested these markers using multiple drugs, and have developed a strategy that are now being taken forward into clinical trial. The trial will help doctors and researchers predict which patient will respond to which one of these drugs, either alone or in combination.

Funding for the trail has come from AstraZeneca and will now be included in the PRIMUS-004 clinical trial as part of the Precision-Panc therapeutic development platform for pancreatic cancer.

PRIMUS-004 is a ground-breaking pancreatic cancer trial, which aims to match patients with more targeted and effective treatment for their tumors. Run by Precision-Panc, a flagship therapeutic development program dedicated to pancreatic cancer—led by the University of Glasgow with major funding from Cancer Research UK—the trial brings a precision medicine approach to pancreatic cancer treatment for the first time in the UK.

The trial will open for recruitment in Glasgow shortly, with 20 other centers throughout the UK to follow.

Although survival for many types of cancer has improved, pancreatic cancer survival has lagged significantly behind in the last 40 years. The disease is particularly hard to treat, partly because it’s often diagnosed at a late stage.

A major limitation to treating pancreatic cancer effectively is that there are very few treatment options for patients with the disease. Currently, some patients with pancreatic cancer cannot repair damaged DNA in the cancer cells, which makes the cancer vulnerable to some new and established drug treatments.

Dr. David Chang, from the University of Glasgow’s Institute of Cancer Sciences, said: “Our study is a huge breakthrough in terms of what might be possible with future treatments. As part of our research, the strategy we’ve developed is extremely promising, and we’re very pleased and proud to see it now be taken into clinical trial. For us, this is a demonstration of a bench-to-bedside precision oncology approach to tackle this terrible disease.”

Michelle Mitchell, Cancer Research UK’s chief executive, said: “We urgently need new ways to treat pancreatic cancer. The disease only has a few treatment options and is generally diagnosed at a late stage, so survival has remained stubbornly low. The Precision Panc study offers a dynamic way to explore new tailored treatments, and it’s fantastic that we now have new drug candidates to add to the PRIMUS-004 trial. We look forward to seeing if these drugs, which have shown promise in the lab, have the same impact for people with pancreatic cancer.”

U.S. signs agreement with AstraZeneca to develop, supply COVID-19 antibody treatment

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc <AZN.L> worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In a video posted on Twitter on Wednesday, Trump credited Regeneron Pharmaceuticals Inc’s <REGN.O> therapeutic for his recovery. Trump received Regeneron’s treatment last week after he was diagnosed with COVID-19.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)

Source Article

U.S. Signs Agreement With AstraZeneca to Develop, Supply COVID-19 Antibody Treatment | Top News

(Reuters) – The U.S. government on Friday signed an agreement with AstraZeneca Plc

worth $486 million to develop and secure supplies of up to 100,000 doses of COVID-19 antibody treatment, a similar class of drugs that was used to treat President Donald Trump.

The U.S. health agency will provide the funding to AstraZeneca for two Phase 3 clinical trials under operation Warp Speed, which is aimed at speeding up treatments and vaccines for COVID-19.

One trial will evaluate the safety and efficacy of the experimental treatment to prevent infection for up to 12 months, in about 5,000 participants, while the second trial will evaluate post-exposure preventative and pre-emptive treatment in roughly 1,100 participants.

AstraZeneca said it plans to supply up to 100,000 doses starting towards the end of 2020 and the US Government can acquire up to an additional one million doses in 2021 under a separate agreement.

In a video posted on Twitter on Wednesday, Trump credited Regeneron Pharmaceuticals Inc’s

therapeutic for his recovery. Trump received Regeneron’s treatment last week after he was diagnosed with COVID-19.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Anil D’Silva)

Copyright 2020 Thomson Reuters.

Source Article

NEC OncoImmunity AS and Oslo University Hospital Team Up to Develop a Diagnostic for COVID-19 Using Artificial Intelligence

NEC OncoImmunity AS (NOI), a subsidiary of NEC Corporation (NEC), and Oslo University Hospital (OUH) are pleased to announce that they have recently been awarded a prestigious grant from the Research Council of Norway (RCN) to develop an artificial intelligence (AI) platform that will enable the rapid design of T-cell diagnostics for emerging or endemic infectious diseases. The project will develop a novel T-cell diagnostic for the current COVID-19 pandemic to complement the current serological tests. This will improve the ability to identify immune responses and acquired immunity, which is desperately needed to deal with the COVID-19 crisis.

Current technologies involve extensive trial and error to define exactly which parts of the pathogen induces robust immunity. These so-called immunodominant epitopes need to be identified for the general population. These demanding, work-intensive and time-consuming steps are necessary to develop tests to monitor the T-cell response to viruses such as SARS-CoV-2 (the infectious virus that causes COVID-19).

Reliable diagnostic tests to identify immune individuals are critical to overcome the ever-looming threat of COVID-19. The AI-based diagnostic to be developed in this project will complement antibody tests and enable individuals who are naturally immune to the virus following infection with SARS-CoV-2 or other seasonal coronaviruses, or who have acquired immunity following vaccination, to be identified.

“Antibody tests are an important aspect of understanding the immune response to the SARS-CoV-2 infection and will remain a mainstay of its diagnosis. However, protective SARS-CoV-2-specific T-cell responses occur in antibody-negative infected individuals who have successfully resolved the infection. In addition, we may already have underlying immunity in the population due to cross reactivity to endemic seasonal human coronaviruses,” said Professor Ludvig A. Munthe Ph.D., Head of Research and Group Leader, Department of Immunology, Oslo University Hospital.

Although the technology to develop antibody diagnostics is readily available, this is not the case for T-cell diagnostics, which currently represents a “blind spot” for the monitoring of immunity to COVID-19 in the world’s population. To address this important gap, NOI and OUH, with the support of RCN, have now committed themselves to develop an AI-designed T-cell diagnostic that monitors the underlying T-cell response to the infection. Developing a reliable T-cell diagnostic comes with specific technological challenges with solutions offered by the NEC Immune Profiler at NOI to cater for the global human population.

“T-cells are known to play a central role for initial and long term immunity against viruses. However, T-cell responses are highly variable between different pathogens and genetic groups in the human population, making the prospect of developing reliable universal T-cell diagnostics for COVID-19 challenging. This challenge has inspired the scientists at NOI to use our AI to seek out the T-cell response to infection as a diagnostic signal. In this project we look forward to adapting the NEC Immune Profiler and other AI technologies at NEC Corporation and leveraging them to develop a COVID-19 T-cell diagnostic for the diverse genetic makeup in the global human population,” said Trevor Clancy Ph.D., Chief Scientific Officer, NEC OncoImmunity

New Study Shows That Playing With Dolls Allows Children to Develop Empathy and Social Processing Skills

Barbie® and neuroscientists from Cardiff University have collaborated on a new study which for the first time uses neuroimaging as evidence to explore the effects of doll play

  • Evidence shows that doll play activates brain regions which are associated with social information processing and empathy, indicating that doll play enables children to rehearse, use and perform these skills even when playing on their own

  • To understand the relevancy of the study, Barbie independently commissioned a global survey in 22 different countries questioning 15,000 parents which showed 91 percent of parents rank empathy as a key social skill they would like their child to develop, but only 26 percent were aware that doll play could help their child develop these skills

  • Today Barbie launches an online hub featuring resources for parents, caregivers, and children, to support them in their social processing skills which has been developed alongside leading empathy expert, writer, and educational psychologist, Dr. Michele Borba

(NASDAQ: MAT): Today, Barbie®, and a team of neuroscientists from Cardiff University, announces findings of a new study conducted using neuroscience for the first time to explore the positive impact doll play has on children, bringing to light new evidence that doll play activates brain regions that allow children to develop empathy and social information processing skills, even when playing by themselves.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005413/en/

NEW STUDY SHOWS THAT PLAYING WITH DOLLS ALLOWS CHILDREN TO DEVELOP EMPATHY AND SOCIAL PROCESSING SKILLS (Photo: Business Wire)

Over the past 18 months, senior lecturer Dr. Sarah Gerson and colleagues at Cardiff University’s Centre for Human Developmental Science have used neuroimaging technology to provide the first indications of the benefits of doll play at a brain level. Through monitoring the brain activity of 33 children* between the ages of 4 and 8, as they played with a range of Barbie dolls, the team found that the posterior superior temporal sulcus (pSTS), a region of the brain associated with social information processing such as empathy, was activated even when the child was playing on their own. These benefits of solo doll play were shown to be equal for both boys and girls.

Dr. Gerson explains: “This is a completely new finding. We use this area of the brain when we think about other people, especially when we think about another person’s thoughts or feelings. Dolls encourage them to create their own little imaginary worlds, as opposed to say, problem-solving or building games. They encourage children to think about other people and how they might interact with each other. The fact that we saw the pSTS to be active in our study shows that playing with dolls is helping them rehearse some of the social skills they will need in later life. Because this brain region has been shown to play a similar role in supporting empathy and social processing across six continents, these findings are likely to be country agnostic“.

To gather the data for the study,

How To Develop Male Breasts

The historical past of train gear dates again to the time of early civilization. There are eight product lines under the Hoist fitness tools house class, particularly, V Select Collection, V-Core Gym, V-Rox, Health club, V Express Gym, V6 Private Pulley Health club, Free weights, PTS Private Training and H MultiStack Gyms.

Reebok originally began life in the north west of England, producing operating and coaching footwear before hitting the big time with their Freestyle aerobics sneakers within the 1980’s which grew to become the shoe of alternative whether or not you worked out or not.

Korean bodybuilder and fitness model Hwang Chul Soon (황철순) was born on September 1, 1983, in Seoul, South Korea. This can be a drawback that you just run into with quite a lot of the fitness fashions from other countries, lack of knowledge. In 1999, Rachel was inducted into the IFBB Hall of Fame along with two other female fitness and bodybuilding stars, Carla Dunlap and Cory Everson.

You realize I joke sometimes about how numerous these models have lengthy resumes. A further by-product of lifting weights is a person can cut back their body fats and improve lean muscle mass. Even those of us who have not always led active existence, growing our bodily activity now will assist us reside longer & healthier lives.

For example, in case you are regularly performing widespread grip chin-ups, the latissimus dorsi muscle tissues in your body have a full workout. But Tianna is an IFBB Bikini Professional, so that locations this pretty 24 12 months old into the Asian fitness category here. I notice though on her web site she continues to be listed as an IFBB Pro Determine Competitor.…